TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that new data on the benefits of maintenance therapy with Ceplene® (histamine dihydrochloride) and interleukin-2 (IL-2) for Acute Myeloid Leukemia (AML) patients in complete remission will be presented at the 50th American Society of Hematology (ASH) Annual Meeting being held December 6-9 at the Moscone Center in San Francisco. Analyses of the pivotal Phase III trial data confirm the consistency and robustness of the Ceplene®/IL-2 effect over control or no treatment to prolong LFS and prevent relapse in AML patients in their first complete remission (CR1). Ceplene® is the first medical therapy to achieve this outcome. Moreover, the improvement in LFS correlated closely with an improved overall survival.
